In a groundbreaking move with the potential to revolutionise the treatment of obesity, Novo Nordisk has entered into a licensing agreement with EraCal Therapeutics to develop and commercialise a small molecule investigational obesity therapeutic to control appetite and body weight. The deal, that could be worth up to US$252.6 M (€235 M), combines EraCal’s cutting-edge technology-based asset with Novo’s commercialisation expertise and global distribution network. The deal boosts Novo’s existing obesity portfolio which is currently led by Wegovy.